GlobeNewswire

MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
11/11/2026
Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue Selected as the cell therapy for the Draper-led team in ARPA-H’s [...]
Boston Concierge Orthopedics Launches New Website Highlighting Shoulder and Knee Care
11/11/2026
Updated website introduces patients to specialized Orthopedic care, direct access to their surgeon, and treatment options across four Massachusetts locations BOSTON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Boston Concierge [...]
LightSolver to Unveil the First Public Demonstration of its All-Optical Computer at SC26
11/11/2026
LightSolver to present its Boeing corrosion-simulation work and join Birds of a Feather (BoF) session on analog computing at the supercomputing conference in Chicago Rehovot, Israel, Nov. 11, 2026 (GLOBE NEWSWIRE) -- [...]
BioAge Labs to Present at Upcoming Investor Conferences
11/11/2026
EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic [...]
Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
11/11/2026
Appointment brings leadership experience building and financing biopharma companies AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on [...]
Beacon Therapeutics to Participate in Jefferies 2026 Global Healthcare Conference in London
11/11/2026
LONDON and CAMBRIDGE, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics (Beacon or the Company), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare [...]
Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
11/11/2026
– Presentations include interim Phase 3 results in women, integrated outcomes from three Phase 3 dialysis access trials and long-term human explant data. – Podium presentation to provide an update on clinical results [...]
aTyr Pharma to Participate in Upcoming Investor Conferences
11/11/2026
SAN DIEGO, Nov. 11, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA [...]
ImvivaBio Presents Longer-Term Data from Clinical Studies of CTA313 Allogeneic CAR-T Therapy in Lupus at the American College of Rheumatology Convergence 2026
11/11/2026
BOSTON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- ImvivaBio, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced new research findings at the American College of [...]
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
11/11/2026
EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative [...]
CenTrak Launches Mobile Capability to Extend Staff Safety Beyond Hospital Walls
11/11/2026
Duress RT Mobile expands staff protection across indoor, outdoor and off-site environments with real-time location visibility through a singularly connected incident management system NEWTOWN, Pa., Nov. 11, 2026 (GLOBE [...]
Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
11/11/2026
CAMBRIDGE, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
11/11/2026
THE WOODLANDS, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced that Company management will participate in a [...]
Ultragenyx to Participate at Investor Conferences in London
11/11/2026
NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra [...]
J-Star Holding Reaffirms 50-Year Advanced Composite Craftsmanship and Executive Financial Commitment, Highlighted by Tier 1 Carbon Fiber Supplier Partnership and Automated U.S. UAV Production
11/11/2026
TAICHUNG CITY, Taiwan, Nov. 11, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), an innovator in advanced composite manufacturing, today issued a corporate update aimed at [...]
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
11/11/2026
DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug [...]
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
11/11/2026
Discussion highlights Vat-Ho’s oncology business development experience, his decision to join Akari and the potential of the Company’s novel PH1 payload platform Watch the “What This Means” video here TAMPA, Fla. and [...]
InnoCare Announces First Patient Dosed in Clinical Trial of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 in China
11/11/2026
BEIJING, Nov. 11, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
11/11/2026
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum